Australia's most trusted
source of pharma news
Sunday, 02 November 2025
Posted 29 October 2025 AM
Montu has accused the Australian Medical Association (AMA) of misinformation relating to medicinal cannabis safety but the doctor's organisation has hit back just as hard at the allegations.
The disagreement centres on Category 5 products which are under the spotlight with the TGA currently reviewing the safety and regulatory oversight of unapproved cannabis products.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.